StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

Acrivon Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

No ev/ebitda figures for Acrivon Therapeutics

Acrivon Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Acrivon Therapeutics figures

See a number that looks wrong?